Serine/Glycine-Free Diet and Dual Modulation of Antitumor Immunity in Colorectal Cancer

Study Background and Research Question

Colorectal cancer (CRC) ranks as the third most common cancer worldwide, with rising mortality rates and limited response to immune checkpoint inhibitors (ICIs) among patients with mismatch repair proficient/microsatellite stable (pMMR/MSS) tumors. Although ICIs targeting the programmed death-1 (PD-1) pathway have revolutionized therapy for some cancers, the majority of CRC patients receive minimal benefit. A central challenge is the metabolic plasticity of cancer cells, which rely on exogenous amino acids such as serine and glycine to fuel rapid proliferation and immune evasion. This context raises the question: can dietary restriction of serine and glycine modulate tumor metabolism and reshape the tumor-immune microenvironment to improve therapeutic outcomes?

Key Innovation from the Reference Study

The study by Tong et al. (2024) introduces a two-pronged mechanism by which a serine/glycine-free (SG-free) diet affects colorectal cancer progression. First, it demonstrates that removing these non-essential amino acids from the diet inhibits tumor growth and enhances antitumor immunity through increased cytotoxic T cell infiltration. Second, the authors reveal that the SG-free diet paradoxically promotes a form of immune evasion via PD-L1 lactylation, a post-translational modification that stabilizes PD-L1 on tumor cells, thus blunting T cell-mediated cytotoxicity. This dual effect highlights new metabolic-immunological interactions and potential targets for combined metabolic and immunotherapy interventions.

Methods and Experimental Design Insights

Tong et al. executed a comprehensive translational approach, combining preclinical murine CRC models with a single-arm, phase I human clinical trial to assess safety and feasibility of SG-free dietary interventions. Key experimental facets included:

• Implementation of SG-free diets in both animal models and human subjects to evaluate impact on tumor progression and systemic immunity.
• Flow cytometry and immunohistochemistry to quantify immune cell populations, especially CD8⁺ T cell infiltration within tumor microenvironments.
• Biochemical and mass spectrometric analyses to detect and characterize PD-L1 lactylation on tumor cells.
• Functional assays examining the effects of PD-L1 lactylation on protein degradation pathways, specifically lysosomal turnover.
• Assessment of patient tolerability and systemic immune markers during dietary intervention.

Of note, the detection of cell proliferation and immune cell dynamics in these experiments relied on advanced flow cytometry cell proliferation assays, leveraging techniques such as click chemistry DNA synthesis detection for precise S-phase measurements—a workflow contextually aligned with the use of EdU Flow Cytometry Assay Kits (Cy5), which utilize copper-catalyzed azide-alkyne cycloaddition (CuAAC) for robust and multiplexed analysis.

Protocol Parameters

• Dietary intervention duration: 2–4 weeks of SG-free diet in preclinical models; 2-week cycles in the human trial, with continuous dietary monitoring.
• Immune cell profiling: Tumor and splenic CD8⁺ T cell analysis by flow cytometry, with S-phase DNA synthesis measured using nucleoside analog-based assays.
• PD-L1 lactylation detection: Immunoprecipitation followed by mass spectrometry and Western blot for lactylation-specific marks on PD-L1.
• Clinical monitoring: Assessment of adverse events, metabolic markers, and immune parameters throughout intervention.

Core Findings and Why They Matter

The SG-free diet significantly slowed colorectal tumor growth in vivo and increased infiltration of cytotoxic CD8⁺ T cells, consistent with enhanced antitumor immunity (Tong et al., 2024). Importantly, the study uncovered that the same dietary intervention led to the accumulation of lactate in the tumor microenvironment, promoting lactylation of the immune checkpoint protein PD-L1. This lactylation delayed PD-L1 degradation by the lysosome, allowing tumor cells to maintain higher surface levels of PD-L1 and thus evade immune attack. Blocking the PD-1/PD-L1 axis with ICIs restored the function of CD8⁺ T cells recruited by the SG-free diet, suggesting that combining dietary modulation with immunotherapy may yield synergistic benefits.

Clinically, the single-arm phase I trial demonstrated that the SG-free diet is feasible and safe for patients, with manageable adverse events and evidence of immune activation. These findings bridge cancer metabolism and immunology, establishing PD-L1 lactylation as a potential therapeutic target and supporting dietary-metabolic interventions as adjuncts to existing immunotherapies.

Comparison with Existing Internal Articles

Several recent internal resources have explored the practical applications of click chemistry DNA synthesis detection and flow cytometry cell proliferation assays in cancer research. For instance, "Unveiling S-Phase Dynamics in Cancer Immunometabolism" discusses the use of EdU Flow Cytometry Assay Kits (Cy5) in dissecting cell cycle dynamics and immunometabolic changes in tumor models, closely mirroring the immunological profiling strategies employed by Tong et al. Similarly, "Reliable Cell Proliferation with EdU Flow Cytometry Assay Kits (Cy5)" offers practical troubleshooting and protocol optimization for S-phase detection, reinforcing the methodological rigor observed in the reference study.

These internal articles emphasize the utility of multiplexed click chemistry-based assays for tracking cell proliferation, immune cell activation, and therapeutic response—paralleling the reference paper's integration of metabolic and immunological endpoints. The ability to combine S-phase DNA synthesis measurement with multiplexed antibody staining enhances the resolution of immune-tumor interactions, a feature that underpins the translational relevance of both the reference study and the internal workflow recommendations.

Limitations and Transferability

While the SG-free dietary intervention showed potent effects in preclinical models and was feasible in a small clinical cohort, several limitations warrant consideration. The sample size of the phase I trial was limited, and longer-term effects on metabolism and patient outcomes remain to be established. The dual role of the SG-free diet—both enhancing immunity and promoting immune evasion via PD-L1 lactylation—underscores the complexity of metabolic interventions. Transferability to other tumor types or broader patient populations requires additional validation, and the mechanistic contributions of other metabolic pathways have yet to be fully elucidated. Furthermore, the dependency on advanced flow cytometry and click chemistry-based DNA synthesis detection for precise immune profiling necessitates access to specialized reagents and instrumentation.

Research Support Resources

To facilitate similar workflows in cancer immunometabolism, researchers may consider using EdU Flow Cytometry Assay Kits (Cy5) (SKU K1078) from APExBIO. These kits employ copper-catalyzed azide-alkyne cycloaddition (CuAAC) for sensitive and reliable detection of DNA synthesis during S-phase, obviating harsh DNA denaturation and enabling multiplexed analysis with cell cycle and immunophenotyping markers. Such tools support robust and reproducible quantification of cell proliferation and immune cell dynamics, as exemplified in the methodologies of Tong et al. For further protocol insights, see internal articles on advanced click chemistry DNA synthesis detection and cell cycle S-phase DNA synthesis measurement in cancer research workflows.